Your shopping cart is currently empty

GSK2200150A is an anti-tuberculosis (TB) agent identified by high-throughput screening (HTS) campaign.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | $38 | In Stock | In Stock | |
| 25 mg | $73 | In Stock | In Stock | |
| 50 mg | $118 | In Stock | In Stock | |
| 100 mg | $176 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $30 | In Stock | In Stock |
| Description | GSK2200150A is an anti-tuberculosis (TB) agent identified by high-throughput screening (HTS) campaign. |
| Targets&IC50 | M. tuberculosis (strain H37Rv):0.38 μM (MIC) |
| In vitro | GSK2200150A, a novel agent with a spirocycle core, exhibits strong antimycobacterial properties against the virulent Mycobacterium tuberculosis strain (H37Rv), demonstrating a minimal inhibitory concentration (MIC) of 0.38 μM [1]. |
| Cell Research | GSK2200150A is tested for activity at either single concentration (100 μM) or serially diluted in 10 μL of purified H2O in triplicate in 96 well microtiter plates. M. tuberculosis H37Rv is grown in complete Middlebrook 7H9 media containing albumin, dextrose and catalase (ADC), 20% Tween 80 and 50% glycerol. A bacterial suspension (90 μL) at OD600 nm of 0.001 is added to the wells and incubated for 7 days. Resazurin (10 μL; 0.05%(w/v)) is then added, incubated for 24 h at 37°C, and fluorescence measured at 590 nm using a FLUOstar Omega microplate reader. After subtraction of background fluorescence from all wells, the percentage mycobacterial survival is determined by comparing the fluorescence of wells containing compounds compared to control wells not treated with compound[1]. |
| Molecular Weight | 357.47 |
| Formula | C20H23NO3S |
| Cas No. | 1443138-53-1 |
| Smiles | C(N1CCC2(CC1)OCCc1sccc21)c1ccc2OCCOc2c1 |
| Relative Density. | 1.31 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (125.88 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.59 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.